| Literature DB >> 35155373 |
Ming Wu1, Qi Zhang1, Qiuyu Zhang1, Huan Wang2, Fawei Wang1,3, Junmei Liu2, Liquan Guo1, Kai Song4.
Abstract
UiO-66, as a member of the MOFs families, is widely employed in sensing, drug release, separation, and adsorption due to its large specific surface area, uniform pore size, easy functionalization, and excellent stability. Especially in electrochemical biosensors, UiO-66 has demonstrated excellent adsorption capacity and response signal, which significantly improves the sensitivity and specificity of detection. However, the existing application research remains in its infancy, lacking systematic methods, and recycling utilization and exclusive sensing of UiO-66 still require further improvement. Therefore, one of the present research objectives is to explore the breakthrough point of existing technologies and optimize the performance of UiO-66-based electrochemical biosensors (UiO-66-EBs). In this work, we summarized current experimental methods and detection mechanisms of UiO-66-EBs in environmental detection, food safety, and disease diagnosis, analyzed the existing problems, and proposed some suggestions to provide new ideas for future research.Entities:
Keywords: UiO-66; biomedical; electrochemical biosensor; environmental; food safety
Year: 2022 PMID: 35155373 PMCID: PMC8825417 DOI: 10.3389/fchem.2022.842894
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
Performance of UiO-66-EBs.
| Detection method | Sample | Linear range | Detection limit | References |
|---|---|---|---|---|
| Fluorescence spectrum | Cysteine and glutathione | 10−11–10−3 M | 10−11 M |
|
| Fluorescence resonance energy transfer | Mercury | 0.1–10 mM | 17.6 nM |
|
| Linear sweep voltammetry | Telomerase | 5 × 102–107 Hela cells/ml | 100 Hela cells/ml |
|
| Fluorescence spectrum | H2S | 0–10 mM | 6.46 μM |
|
| Electrochemical impedance spectroscopy | Hydroquinone, catechol and resorcinol | 0.5–100 μM, 0.4–100 μM and 30–400 μM | 0.056, 0.072 and 3.51 μM |
|
| Square wave voltammetry | Kanamycin and chloramphenicol | 0.002–100 nM | 0.16 and 0.19 pM |
|
| Electrochemical impedance spectroscopy and differential | Carcinoembryonic antigen | 0.01–10 ng/ml | 8.88 and 4.93 pg/ml |
|
| Electrochemical impedance spectroscopy | PKA | 0.005–50 μ/ml | 0.0049 μ/ml |
|
| Electrochemical impedance spectroscopy | Diethylstilbestrol | 0.1 pg/ml–20 ng/ml | 0.06 pg/ml |
|
| Fluorescence measurements | ATP | 0–1 μM | 35 nM |
|
| Differential pulse voltammetry indicated | The | 0.02–1,000 pg/ml | 10 fg/ml |
|
| Electrochemical impedance spectroscopy | PKA | 0.015–80 μ/ml | 0.009 μ/ml |
|
| Voltammetry | Organophosphorus compounds | 0.01–150 nM | 0.004 nM |
|
| Electrochemical impedance spectroscopy and differential pulse voltammetry | Patulin | 5 × 10−8–5 × 10−1 μg/ml | 1.46 × 10−8 μg/ml |
|
| Cyclic voltammetry and electrochemical impedance spectroscopy | Prostate specific antigen | 0.0001–10 ng/ml | 0.038 pg/ml |
|
| Combining of amperometric and square wave voltametric methods | Amyloid β-protein | 10 fg/ml–100 ng/ml | 3.35 fg/ml |
|
| The obtained electrochemical impedance | The cancer cell | 1.0 × 102–1.0 × 106 cells/ml | 90 cells/ml |
|
| Differential pulse voltammetry indicated | Let-7a and microRNA-21 | 0.01–10 pM and 0.02–10 pM | 3.6 and 8.2 fM |
|
| Cyclic voltammetry and electrochemical impedance spectroscopy | Breast cancer biomarker CA15-3 | 5 × 10−4–5 × 102 μ/ml | 1.7705 × 10−5 μ/ml |
|
| Electrochemical impedance spectroscopy measurements | N6-methyladenosine | 0.05–30 nM | 0.0167 nM |
|
| Differential pulse voltammetry indicated | Cardiac troponin I | 0.01–100 ng/ml | 5.7 pg/ml |
|
| Cyclic voltammetry and square wave voltammetry | Antibiotics | 25–900 nM | 13 nM |
|
| Cyclic voltammetry and electrochemical impedance spectroscopy | Ochratoxin A | 0.1 fM–2.0 μM | 0.079 fM |
|
| Cyclic voltammetry | Low density lipoprotein | 1.0 ng/ml–100 μg/ml | 0.3 ng/ml |
|
| Cyclic voltammetry and differential pulse voltammetry | MicroRNA-21 | 20 fM–600 pM | 0.713 fM |
|
| Electrochemical impedance spectroscopy measurements | β-amyloid | 10−5–50 ng/ml | 3.32 fg/ml |
|
| Electrochemical impedance spectroscopy measurements | Osteopontin | 0.01 pg/ml–2.0 ng/ml | 4.76 fg/ml |
|
| Cyclic voltammetry and Electrochemical impedance spectroscopy | NT-proBNP | 1 fg/ml–100 ng/ml | 0.41 fg/ml |
|
| Cyclic voltammetry and electrochemical impedance spectroscopy | Living Michigan cancer foundation-7 cancer cells | 100–100,000 cell/ml | 31 cell/ml |
|
| Electrochemical impedance spectroscopy | CEA | 50 fg/ml–10 ng/ml | 16 fg/ml |
|
| Ratiometric fluorescent method | Detection of dopamine and reduced glutathion | 4–50 μM and 1–70 μM | 0.68 and 0.57 μM |
|
| Cyclic voltammetry, differential pulse voltammetry and electrochemical impedance spectroscopy | Tetracycline | 1.0 × 10−6–6.0 × 10−5 mol/L | 8.94 × 10−7 mol/L |
|
| Electrochemical impedance spectroscopy and cyclic voltammetry | Nitrogenous diphenyl ether pesticide | 0–100 μM | 0.026 μM |
|
| Square wave voltametric methods and electrochemical impedance spectroscopy |
| 10–109 cfu/ml | 3 cfu/ml |
|
| Colorimetric and spectrofluorometric techniques | Cholesterol quantification | 0.04–1.60 μmol/L | 0.01 μmol/L |
|
| Photoelectrochemical and electrochemical tests | PKA | 0.001–100 μ/ml | 0.00035 μ/ml |
|
| Fluorescence spectra | Bacterial | 2.5 × 104–5.0 × 104 CFU/ml | 1.0 CFU/ml |
|
| Resistance method | Exosomes-derived | 1.0 × 103–1.0 × 108 Particles/ml | 300 Particles/ml |
|
| Differential pulse voltammetry indicated | Procalcitonin | 1 pg/ml–100 ng/ml | 0.3 pg/ml |
|
| Linear sweep voltammetry | Alpha-fetoprotein | 1 fg/ml–100 ng/ml | 0.2 fg/ml |
|
| Electrochemical impedance spectroscopy | ATP | 1.0 × 10−5–5.0 ng/ml | 1.69 fg/ml |
|
| Cyclic voltammetry | Glucose | 1–10 mM | 5 μM |
|
| Electrochemical impedance spectroscopy and cyclic voltammetry | ATP | 1.0 × 10−5–5.0 ng/ml | 5.04 fg/ml |
|
FIGURE 1Table of contents graphic.